Clinical data | |
---|---|
Pronunciation | /fɛnˈɛθələmiːn/ |
Dependence liability |
Psychological: low–moderate Physical: none |
Addiction liability |
None–Low (w/o an MAO-B inhibitor) Moderate (with an MAO-B inhibitor) |
Routes of administration |
Oral (taken by mouth) |
Drug class | CNS stimulant |
ATC code |
|
Physiological data | |
Source tissues |
Substantia nigra pars compacta; Ventral tegmental area; Locus coeruleus; many others |
Target tissues | System-wide |
Receptors | Varies greatly across species; Human receptors: hTAAR1, hTAAR2 |
Precursor | L-Phenylalanine |
Biosynthesis | Aromatic L-amino acid decarboxylase (AADC) |
Metabolism | Primarily: MAO-B Other enzymes: MAO-A, SSAOs, PNMT, AANAT, FMO3, and others |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Primarily: MAO-B Other enzymes: MAO-A, SSAOs, PNMT, AANAT, FMO3, and others |
Biological half-life | Exogenous: 5–10 minutes Endogenous: ~30 seconds |
Excretion | Renal (kidneys) |
Identifiers | |
|
|
Synonyms | PEA, 1-amino-2-phenylethane |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
NIAID ChemDB | |
ECHA InfoCard | 100.000.523 |
Chemical and physical data | |
Formula | C8H11N |
Molar mass | 121.18 g/mol |
3D model (Jmol) | |
Density | 0.9640 g/cm3 |
Melting point | −60 °C (−76 °F) |
Boiling point | 195 °C (383 °F) |
|
|
|
|
Phenethylamine (PEA), also known as β-phenylethylamine (β-PEA) and 2-phenylethan-1-amine, is an organic compound, natural monoamine alkaloid, and trace amine which acts as a central nervous system stimulant in humans.
Phenylethylamine functions as a monoaminergic neuromodulator and, to a lesser extent, a neurotransmitter in the human central nervous system. It is biosynthesized from the amino acid L-phenylalanine by enzymatic decarboxylation via the enzyme aromatic L-amino acid decarboxylase. In addition to its presence in mammals, phenethylamine is found in many other organisms and foods, such as chocolate, especially after microbial fermentation. It is sold as a dietary supplement for purported mood and weight loss-related therapeutic benefits; however, orally ingested phenethylamine is primarily metabolized in the small intestine by monoamine oxidase B (MAO-B) and then aldehyde dehydrogenase (ALDH), which convert it to phenylacetic acid. This prevents significant concentrations from reaching the brain when taken in low doses.